Artelo Biosciences (ARTL) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on therapeutics targeting lipid-signaling modulation pathways, including the endocannabinoid system.

• Pipeline includes ART27.13 (dual cannabinoid agonist for cancer-related anorexia), ART26.12 (FABP5 inhibitor for chemotherapy-induced peripheral neuropathy and other indications), and ART12.11 (proprietary CBD cocrystal for multiple potential indications).

• Product candidates are developed in accordance with regulated drug development standards, aiming for prescription-based commercialization post-approval.

• Holds patents and licenses for key programs, with global intellectual property coverage for lead assets.

Financial performance and metrics

• Aggregate market value of outstanding common stock held by non-affiliates was $22,988,288.08 as of May 1, 2026.

• During the 12-month period ending on the date of the prospectus, securities with an aggregate market value of $5,706,345.75 were sold.

Use of proceeds and capital allocation

• Net proceeds intended for working capital and general corporate purposes.

• May allocate a portion to acquire, license, or invest in technologies, products, or businesses to enhance company value.

• Pending use, proceeds will be invested in short- and intermediate-term, interest-bearing obligations or investment-grade instruments.